Numbers

The Numbers

Daqo trades like a net-cash commodity producer whose product price is still below its cost curve: the balance sheet can absorb losses, but the stock will not rerate until polysilicon ASPs recover above Daqo's roughly $6.61/kg FY2025 production cost and stay there. The contradiction is stark: consolidated cash is larger than the public market cap, yet FY2025 gross margin was negative 20.7% and Q1 2026 revenue fell to $26.7M, so the market is pricing cash-trap and cycle risk more than asset value.

The supplied data did not include the proprietary Quality Score, Predictability, sub-rank, or Fair Value fields. I do not substitute invented values; the scorecard below uses statement-derived health and forensic proxies instead.

Economic Engine

Daqo is a focused China-based polysilicon producer: revenue is almost entirely a function of sales volume multiplied by spot-linked polysilicon ASP, while cost position is driven by electricity, metallurgical silicon, depreciation, and utilization. The Phase 5 expansion lifted nameplate capacity to 305,000 MT, but that scale became a burden when industry oversupply pushed prices below cost.

The 2021-2022 supercycle was real, but the same chart shows why the stock is hard to underwrite: by FY2024 and FY2025 the company was back to negative gross and operating margins.

This is the operating chart that matters most: FY2025 ASP was about $5.25/kg against production cost of $6.61/kg, so higher volume alone cannot fix earnings.

The late-2025 bounce did not hold: Q1 2026 revenue was down 78.4% year over year as sales volume collapsed.

Health Check

Is this a well-run business that will still be around in 10 years? The balance sheet says survival is plausible; the returns and forensic flags say compounding is not back until unit economics normalize.

Trailing five-year FCF was only 39.7% of Daqo-attributable net income because the company poured cash into Phase 5 expansion just as the cycle rolled over.

Capital allocation has been capacity-first: buybacks were meaningful in 2022-2023, but capex was the dominant call on cash and there is no common dividend in the cash-flow data.

The balance sheet is the best part of the story: FY2025 cash was $1.94B with no reported debt, although Daqo's 72.8% ownership of Xinjiang Daqo means consolidated cash is not the same as unrestricted parent-level cash.

Market View

The staged valuation history is seven years, not 20; current P/B is 0.66 standard deviations below that available history and below the 2021-2025 mean, but the discount is tied to negative returns rather than simple neglect.

Daqo screens better on liquidity and worse on operating margin than most peers; the market is giving little credit for cash because the commodity cycle and China/ADR structure dominate the simple balance-sheet math.

Fair Value Range

The supplied Fair Value field was unavailable, so the range below uses a simple book-value reversion method. That is appropriate for a capital-intensive commodity producer with negative earnings; it is also blunt, because it says nothing about the timing of polysilicon price repair.

The numbers confirm that Daqo still has a major balance-sheet cushion and real low-cost scale; they contradict any simple "cheap because below cash" narrative because current gross profit, ROIC, and Q1 2026 sales volume are deeply impaired; the metric to watch next is the ASP-to-production-cost spread, since a sustained move back above cost would change both free cash flow and the book-multiple argument fastest.